2023-09-14 04:51:56 ET
Astellas Pharma ( OTCPK:ALPMY ) intends to build a new facility, at an approximate cost of €330M in Tralee, Co. Kerry. Ireland.
This investment will expand capacity and capabilities for aseptic drug products, reinforce stable production for global supply and aid the development and commercialization of innovative antibody drugs and other new products.
The facility will be based on the Industrial Development Authority's greenfield site in Kerry Technology Park, Tralee.
Construction will commence in 2024, with the site expected to be operational by 2028.
More on Astellas Pharma ADR
- Financial information for Astellas Pharma ADR
- Astellas: Earnings Power, Asset Factors Attractive, Reiterate Hold On Valuation
- Apellis falls as Astellas wins FDA nod for rival product
- Poseida jumps on $50M investment from Astellas
For further details see:
Astellas Pharma to build a new $330M facility in Ireland